

# A Pharmacological Master Key Mechanism that Unlocks the Selectivity Filter Gate in K<sup>+</sup> Channels

## Authors:

Marcus Schewe<sup>1†\*</sup>, Han Sun<sup>2†</sup>, Ümit Mert<sup>1</sup>, Alexandra Mackenzie<sup>3,4,5</sup>, Ashley C. W. Pike<sup>3</sup>, Friederike Schulz<sup>1</sup>, Cristina Constantin<sup>6,7</sup>, Kirsty S. Vowinkel<sup>8</sup>, Linus J. Conrad<sup>4,5</sup>, Aytug K. Kiper<sup>8</sup>, Wendy Gonzalez<sup>9,10</sup>, Marianne Musinszki<sup>1</sup>, Marie Tegtmeier<sup>1</sup>, David C. Pryde<sup>11</sup>, Hassane Belabed<sup>12</sup>, Marc Nazare<sup>12</sup>, Bert L. de Groot<sup>13</sup>, Niels Decher<sup>8</sup>, Bernd Fakler<sup>6,7</sup>, Elisabeth P. Carpenter<sup>3,4</sup>, Stephen J. Tucker<sup>4,5</sup> & Thomas Baukrowitz<sup>1\*</sup>

## Affiliations:

<sup>1</sup>Institute of Physiology, Christian-Albrechts University of Kiel, 24118 Kiel, Germany.

<sup>2</sup>Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Department of Structural Biology, 13125 Berlin, Germany.

<sup>3</sup>Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, United Kingdom.

<sup>4</sup>OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford OX1 3PN, United Kingdom.

<sup>5</sup>Clarendon Laboratory, Department of Physics, University of Oxford, Oxford OX1 3PU, United Kingdom.

<sup>6</sup>Institute of Physiology II, Albert-Ludwigs University of Freiburg, 79104 Freiburg, Germany.

<sup>7</sup>Centers for Biological Signaling Studies CIBSS and BIOSS, 79104 Freiburg, Germany.

<sup>8</sup>Institute of Physiology and Pathophysiology, Vegetative Physiology, Philipps-University of Marburg, 35037 Marburg, Germany.

<sup>9</sup>Centro de Bioinformatica y Simulacion Molecular, Universidad de Talca, 3465548 Talca, Chile.

<sup>10</sup>Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD), Universidad de Talca, 3465548 Talca, Chile.

<sup>11</sup>Pfizer Worldwide Medicinal Chemistry, Neuroscience and Pain Research Unit, Portway Building, Granta Park, Great Abington, Cambridgeshire CB21 6GS, United Kingdom.

<sup>12</sup>Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Department of Medicinal Chemistry, 13125 Berlin, Germany.

<sup>13</sup>Computational Biomolecular Dynamics Group, Max Planck Institute for Biophysical Chemistry, 37077 Göttingen, Germany.

†These authors contributed equally to this work

\*Correspondence authors

M.S. <https://orcid.org/0000-0002-6192-5651>

T.B. <https://orcid.org/0000-0003-4562-0505>

**Abstract:**

Potassium channels have been evolutionarily tuned for activation by diverse biological stimuli, and pharmacological activation is thought to target these specific gating mechanisms. Here we report a class of negatively charged activators (NCAs) that bypass the specific mechanisms but act as master keys to open  $K^+$  channels gated at their selectivity filter (SF), including many  $K_{2P}$  channels, voltage-gated hERG channels and  $Ca^{2+}$ -activated BK-type channels. Functional analysis, X-ray crystallography and molecular dynamics simulations revealed that the NCAs bind to similar sites below the SF, increase pore and SF  $K^+$  occupancy and open the filter gate. These results uncover an unrecognized poly-pharmacology among  $K^+$  channel activators and highlight a filter gating machinery that is conserved across different families of  $K^+$  channels with implications for rational drug design.

**Short title:**

Poly-pharmacology of  $K^+$  channel activation

**One sentence summary:**

A class of negatively charged compounds activate structurally distinct  $K^+$  channels via a conserved mechanism.

## Main Text:

Dampening cellular electrical activity by pharmacological activation of specific types of  $K^+$  channels has therapeutic potential for the treatment of a variety of disease states including epilepsy, arrhythmias, vascular constriction or various pain conditions (1, 2). Consequently, screening efforts have identified a number of agents that open various different types of  $K^+$  channels (2) presumably by targeting their respective channel-specific activation mechanisms.

Distinct structural mechanisms enable  $K^+$  channels to respond to a plethora of physiological stimuli including voltage, temperature, mechanical force, and various second messengers, such as ATP,  $Ca^{2+}$ , and  $H^+$ , as well as bioactive lipids such as  $PIP_2$  and arachidonic acid (3, 4). However, despite this complexity, these activation pathways seem to converge on the two principal mechanisms known to gate  $K^+$  channels open - dilation of the 'lower' gate at the intracellular pore entrance employed by inwardly-rectifying ( $K_{ir}$ ) (5) and voltage-gated ( $K_v$ )  $K^+$  channels (6), and activation of the selectivity filter (SF) gate used by most two-pore domain  $K^+$  ( $K_{2P}$ ) channels (4, 7, 8) and  $Ca^{2+}$ -activated ( $BK_{Ca}$ , Slo)  $K^+$  channels (9, 10). In voltage-gated hERG channels, both mechanisms co-exist with voltage opening the lower gate, but rapid inactivation occurring through closure of the SF gate (11, 12). Here we identify a common mechanism for drug-induced channel opening that bypasses these physiological activation mechanisms in SF-gated  $K^+$  channels.

For the mechanosensitive  $K_{2P}$  channels TREK-1 and TREK-2, the voltage-gated hERG and the  $Ca^{2+}$ -activated  $BK_{Ca}$  channels, a series of small molecule activators all harboring a negatively charged group (tetrazole or carboxylate) have been proposed to act as selective channel openers (i.e. BL-1249 for TREK-1/-2 (13); PD-118057 for hERG (14); and NS11021 for  $BK_{Ca}$  (15)). However, application of these compounds to their respective 'non-target' channels revealed an unexpected poly-pharmacology: all three openers displayed equal efficiency in opening TREK-1 channels (Fig. 1A), hERG channels (Fig. 1B), as well as  $BK_{Ca}$  channels (Fig. 1C) whose activation curve is strongly shifted to more negative voltages (fig. S1C). This suggests they may not target channel specific activation mechanisms and may instead share a common mechanism. In all cases the compound-mediated effect was effectively antagonized by large quaternary ammonium ions ( $QA_L^+$ ) such as tetra-pentyl-ammonium (TPenA) or tetra-hexyl-ammonium (THexA) that are known to block  $K^+$  channels at a site immediately below the inner entrance to the SF (16) (Fig. 1, A and B and fig. S1C). Likewise, all these activators reduced the  $QA_L^+$ -mediated inhibition in these different  $K^+$  channels (Fig. 1C and, figs. S1, A and B and S7, A and B). Furthermore, extended screening

with BL-1249 also revealed potent activation of several other  $K_{2P}$  channels (TREK-2, TRAAK, TALK-1, TALK-2, THIK-1 and THIK-2; fig. S1D). Together, these data suggest that these negatively charged activators (termed NCAs) (BL-1249, PD-118057 and NS11021) act on a gating mechanism that is shared among these different classes of  $K^+$  channels, and that their action involves a site that overlaps with the conserved  $QA_L^+$ -binding site located below the SF filter.

A distinctive feature of all NCA-responsive  $K^+$  channels is their gating by the SF, a mechanism that is intimately coupled to ion permeation (17, 18). In  $K_{2P}$  channels this coupling leads to pronounced activation by  $Rb^+$ , which displays an ion occupancy distinct to  $K^+$  at the four SF  $K^+$  binding sites (S1 to S4) and this stabilizes the activated state of the SF gate (17). Interestingly,  $Rb^+$  not only activated all NCA-responsive  $K_{2P}$  channels, but also led to robust activation of  $BK_{Ca}$  and hERG channels (Fig. 1D). In contrast,  $Rb^+$  failed to exert any activatory effect on  $K^+$  channels gated at the helix bundle-crossing (i.e.  $K_{ir}$  and most  $K_v$  channels) as was observed for  $K_v1.1$ ,  $K_v1.5$ ,  $K_v3.1$  and  $K_{ir1.1}$  (Fig. 1D); in line, these channels were also not activated by BL-1249 (fig. S2, A to E). Furthermore, CNG channels that are also gated at the SF, were not activated by BL-1249 indicating that the NCA mechanism may be specific to SF-gated  $K^+$  channels (fig. S2F).

To gain further mechanistic insight into channel opening by the NCAs, we next investigated their binding by X-ray crystallography, cysteine-scanning mutagenesis and atomistic molecular dynamics (MD) simulations. First, anomalous diffraction data were collected from TREK-2 channels co-crystallized with a brominated derivative of BL-1249 (BL-1249<sup>Br</sup>) (Fig. 2A and fig. S3, A to C, and supplementary materials, materials and methods). Although no discrete electron density was visible for BL-1249 itself, in anomalous difference maps two bromine peaks were clearly visible per TREK-2 dimer (fig. S3, A and B) and the mainchain protein backbone showed excellent agreement with a previously crystallized high-resolution structure of TREK-2 [Protein Data Bank (PDB) ID: 4XDJ] (19). Both bromine anomalous difference peaks were located at the entrance of the side fenestrations branching off the central pore cavity below the SF. Comparison with a structure that included  $QA_L^+$  (16) showed these bromine positions reside within the spherical volume of THexA, but outside that of the smaller tetra-ethyl-ammonium (TEA) ion. Consistent with this, BL-1249 activation of TREK-2 channels was antagonized by THexA, but not by TEA (Fig. 2, B and C).

These structural data were complemented by cysteine-scanning mutagenesis of the pore-lining M2 and M4 helices of TREK-1. Six residues including the highly conserved P183

and L304 (also investigated in TREK-2, fig. S3D) were identified where mutations markedly reduced the apparent affinity of BL-1249. These residues cluster around the bromine densities detected in the TREK-2 co-crystal with BL-1249<sup>Br</sup> (Fig. 2D and fig. S3, C and D). A role for L304 in this presumed binding site was further supported by cysteine-modification protection experiments where the time course of irreversible pore blockade induced by application of the cysteine-modifying agent MTS-TBAO (20) to TREK-1 L304C channels was markedly slowed by the presence of BL-1249 (Fig. 2, E and F). This effect was specific for BL-1249, as two further channel activators with distinct binding sites (2-APB at the C-terminus (21) and ML335 behind the SF (22)) both failed to slow this rate (Fig. 2, E and F). Furthermore, TREK-1 activation with 2-APB or ML335 was not antagonized by QA<sub>L</sub><sup>+</sup> inhibition and mutations at the BL-1249 site did not affect 2-APB activation (figs. S4, A and B and S4E).

In addition, we performed MD simulations to examine the orientation of BL-1249<sup>Br</sup> within its proposed binding site (Fig. 2G). The favoured binding pose oriented the negatively charged tetrazole group of BL-1249 towards the S6 ‘cavity binding site’ for K<sup>+</sup> just below the SF. The remainder of the BL-1249 molecule engaged with residues in M2 and M4 consistent with our scanning mutagenesis data (Fig. 2D and fig. S3D). Moreover, the bromine atom in these simulations was found to be within 3 - 4 Å of the bromine densities determined by crystallography (fig. S3E). Together, these data indicate binding of BL-1249 to a site below the SF and reveal a critical role of the negative charge of the acidic tetrazole ring (pK<sub>a</sub> around 5) implying a pH-dependent compound efficacy. Indeed, when tested with the K<sub>2P</sub> channel TALK-2 (exhibiting little intrinsic intracellular pH (pH<sub>i</sub>) sensitivity) BL-1249 potency dropped strongly with lowering the solution pH<sub>i</sub> to 5 while control experiments with 2-APB lacked this pH dependence (Fig. 3F).

We have recently used atomistic MD simulations and a double-bilayer setup to study ion permeation in the TRAAK K<sub>2P</sub> channel (17). We, therefore, carried out simulations of ion permeation in TRAAK with BL-1249 modelled into the equivalent site in the TRAAK channel structure [PDB ID: 4I9W] (Fig. 3A). This indicated several changes induced by BL-1249: (i) K<sup>+</sup> occupancy at the S6 site located adjacent to the negatively charged tetrazole group of BL-1249 increased ~16-fold (Fig. 3, A and B), (ii) increased K<sup>+</sup> occupancy of the S1 and S4 sites (Fig. 3B), and (iii) increased the rate of K<sup>+</sup> permeation by 1.6-fold (24 ± 2 ions/μs compared to 15 ± 2 ions/μs without BL-1249; Fig. 3C).

The effect of BL-1249 on ion permeation was further investigated with single channel recordings of TREK-2 expressed in HEK293 cells. Besides an increase in open probability, an increase in the measured single channel amplitude was also observed in both the inward

(from  $-29.3 \pm 1.5$  pA to  $-34.1 \pm 1.9$  pA at  $-100$  mV;  $n = 7$ ) and outward (from  $17.7 \pm 1.3$  pA to  $21.7 \pm 1.4$  pA at  $+100$  mV;  $n = 7$ ) directions in response to BL-1249 (Fig. 3, D and E). This result is consistent with the observed increase in SF ion occupancy at S1 and S4 that is expected to enhance ion permeation via a direct knock-on effect for ions entering the SF from either side (23). A similar increase in unitary conductance was also observed for TREK-1 channels recorded in patches from *Xenopus* oocytes (fig. S4, A to C). Notably, increases in single channel conductance have not been observed upon activation of TREK-1, TREK-2 or TRAAK  $K_{2P}$  channels by other physiological stimuli (24, 25).

Collectively, these results indicated that BL-1249 increases ion permeation and channel open probability by influencing  $K^+$  occupancy at sites below and within the SF. In line with this notion, mutations in the SF that change filter ion occupancy at the S1 and S4 sites (17, 26) and induce the activated ‘leak mode’ in  $K_{2P}$  channels (17), also render them insensitive to BL-1249 (and various other activators discussed below; fig. S6, A to D).

The negatively charged moiety identified within BL-1249, PD-118057 and NS11021 is also found in a series of known activators of TREK-1/-2  $K_{2P}$  channels (ML67-33 (27), tetrazole; DCPIB (28), carboxylate), hERG channels (PD-307243 (29), carboxylate; NS3623 (30), tetrazole) and  $BK_{Ca}$  channels (GoSlo-SR-5-6 (31), sulphonate) and its requirement for channel activation has been demonstrated for ML67-33 and GoSlo-SR-5-6 (27, 31). In fact, these compounds also share all the hallmark features of BL-1249 action, including poly-pharmacology (i.e. mutual activation of  $K_{2P}$ ,  $BK_{Ca}$  and hERG channels (Fig. 4, C and D), sensitivity to  $QA_L^+$  (Fig. 4A and fig. S7, A to C, and tables S2 and S3) and mutations that reduce BL-1249 activation in TREK-1 (fig. S4, C and D). In addition, MD simulations of their interaction with structures of the TREK-2,  $BK_{Ca}$  and hERG channel pores identified similar stable binding poses below the SF with orientation of the negative moiety towards the cavity, and a concomitant increase in  $K^+$  occupancy at cavity and SF ion binding sites (Fig. 4, C and D, and figs. S8, A to C and S7D). Notably, this assumed NCA binding site overlaps with the ‘promiscuous inhibitor binding site’ in the hERG channel, which underlies drug-induced long QT syndrome (12, 32). This site is thought to accommodate many hydrophobic molecules (e.g. terfenadine) and consistent with this we found that activation by PD-118057 strongly reduced inhibition by terfenadine (Fig. 4B).

The molecular features of the NCA compounds define a common pharmacophore which, besides the negatively charged group, comprises both aromatic and hydrophobic moieties (Fig. 4E). As a control we tested tetrazole-containing compounds that do not fit this

common pharmacophore on TREK-1, BK<sub>Ca</sub> and hERG channels and found they were unable to promote channel activation (fig. S9, A to C).

In summary, our results uncover a class of K<sup>+</sup> channel openers, the NCAs, that act as a universal master-key to unlock the SF gate. Mechanistically, these NCAs bind below the SF where their negative charge promotes K<sup>+</sup> binding to the pore cavity and, thereby, also alter the ion occupancy in the SF in a way that is known to promote activation of the filter gate (17). We hypothesize that in particular, the increase at the S1 and S4 sites is responsible for activating the SF gate because all NCA-responsive channels are also activated by Rb<sup>+</sup> permeation, which is thought to increase ion occupancy at these sites, whilst mutations known to reduce S1 and S4 ion occupancy in K<sub>2P</sub> channels abolish NCA activation. Furthermore, a loss of K<sup>+</sup> binding to the S1 site has been implicated in SF inactivation in K<sub>v</sub> channels (33), hERG channels (32), and TREK-2 K<sub>2P</sub> channels (19). However, we cannot currently exclude the possibility that non-electrostatic interactions of the NCAs with their respective binding sites also contribute to the stabilization of the active SF state as these sites involve gating sensitive regions (i.e. the TM4 (8, 19) and S6 segments (6, 34)). In any case, our results support the view that many K<sub>2P</sub> channels, as well as BK<sub>Ca</sub> channels adopt a low activity (i.e. inactivated) state of their SF at rest, and that the various physiological stimuli induce structural changes that drive the SF into an active (open) state. The NCAs appear to operate via bypassing these activation mechanisms to directly stabilize the SF in its active state.

In addition, our findings have significant implications for the development of drugs that target K<sup>+</sup> channels as they reveal the binding sites and the mechanism of action for many established activators in various K<sup>+</sup> channels, and also identified the first activators for several K<sub>2P</sub> channels (e.g. TALK-1/-2 and THIK-1/-2). Notably, the NCA binding site overlaps with the promiscuous inhibitor site in hERG and, thus, targeting this NCA site might represent a promising approach to circumvent the drug-induced long QT syndrome currently a serious burden in drug development (12). However, the identified poly-pharmacology also represents a challenge for the development of any NCA based compound into a highly subtype-specific K<sup>+</sup> channel agonist. Nevertheless, structural differences between K<sub>2P</sub>, hERG and BK<sub>Ca</sub> channel may still permit a rational drug design that reduces this promiscuity. However, in some acute situations such as ischemic stroke or status epilepticus, exploiting the poly-pharmacology of NCAs to promote simultaneous opening of multiple neuroprotective K<sup>+</sup> channels (e.g. BK<sub>Ca</sub>, TREK-1/-2, TRAAK, and THIK-1/-2), may even be beneficial.




Fig. 1. Negatively charged activators (NCAs) open SF-gated K<sup>+</sup> channels via a similar site.

**Fig. 1. Negatively charged activators (NCAs) open SF-gated K<sup>+</sup> channels via a similar site.** (A) Representative TREK-1 channel currents recorded in inside-out (i-o) patches evoked by voltage ramps in the absence (basal) and presence of the indicated compounds. BL-1249 (compound structure depicted) dose-response curves represent currents at +40 mV  $\pm$  5  $\mu$ M THexA that produced  $77 \pm 6\%$  inhibition of basal currents ( $n \geq 8$ ). (B) hERG channel currents (voltage steps from -80 mV to +60 mV) in i-o patches  $\pm$  the indicated compounds; arrows indicate peak tail current amplitudes at -100 mV. PD-118057 dose-response curves represent normalized tail currents  $\pm$  1  $\mu$ M TPenA that produced  $91 \pm 1\%$  inhibition of basal currents ( $n \geq 6$ ). (C) BK<sub>Ca</sub> channel currents (voltage steps from a holding potential of -80 mV to +100 mV (zero Ca<sup>2+</sup>)) in i-o patches  $\pm$  the indicated compounds. THexA inhibition represents currents at +100 mV  $\pm$  50  $\mu$ M NS11021 (compound structure depicted;  $n \geq 11$ ). (D) Bars  $\pm$  S.E.M represent fold change of outward currents upon exchange of intracellular

$K^+$  by  $Rb^+$  for  $K_{2P}$  and  $BK_{Ca}$  channels (+100 mV), for hERG,  $K_v1.1$ ,  $K_v1.5$ ,  $K_v3.1$  channels (+60 mV) and  $K_{ir}1.1$  channels (+40 mV). The channels are grouped as either SF-gated/NCA-activated or HBC (helix-bundle crossing)-gated. (E) Representative traces of  $Rb^+$  activation for  $BK_{Ca}$ , TREK-1 and hERG channels using indicated protocols (arrow indicates the starting point of hERG inactivation after inactivation recovery (at -100 mV)).  $\tau$  values from mono-exponential fits to inactivation time course ( $n \geq 12$ ).




Fig. 2. Identification of the BL-1249 binding site in TREK  $K_{2P}$  channels.

**Fig. 2. Identification of the BL-1249 binding site in TREK  $K_{2P}$  channels.** (A) The structure depicts TREK-2 (PDB ID: 4XDJ), with pink spheres representing the positions of Br atoms in a brominated BL-1249 derivative (BL-1249<sup>Br</sup>) obtained by co-crystallization of TREK-2 and BL-1249<sup>Br</sup> (see also fig. S3). With this medium resolution data only the Br atoms were identified, as they gave peaks in anomalous difference maps. (B) The same

structure also showing spherical representations of THexA (green) and TEA (dark blue) with their central nitrogen atoms (yellow). Their positions are based on the crystal structures of KcsA with QA<sup>+</sup>s (16). Note the Br atoms (pink) are within the sphere of THexA, but not of TEA. (C) BL-1249 dose-response curves for TREK-2 ± 100 mM TEA (n ≥ 12) or 5 μM THexA (n ≥ 13) (TEA and THexA produce 74 ± 3 % and 83 ± 2 % basal current inhibition, respectively). (D) Scanning mutagenesis of M2 and M4 helices showing BL-1249 EC<sub>50</sub> values ± S.E.M determined at +40 mV; inset shows a K<sub>2P</sub> channel alignment for channels strongly activated by BL-1249 (see also fig. S1D) with residues homologous to TREK-1 P183 and L304 highlighted. (E) Time courses of 10 μM MTS-TBAO cysteine modification of L304C in TREK-1 before and after maximal activation by BL-1249 (50 μM), ML335 (50 μM) and 2-APB (1 mM) (left panel). Cartoon depicts TREK-1 with predicted drug binding sites relative to position of residue L304C. (F) Time values ± S.E.M for half maximal MTS-TBAO modification inhibition (t<sub>1/2</sub>) in presence of different agonists. (G) Representation of favoured binding pose of BL-1249 (pink) in TREK-2 along with location of the TREK-1 corresponding mutations (green) that reduce BL-1249 activation.




Fig. 3. Effects of BL-1249 on pore K<sup>+</sup> occupancy and permeation.

**Fig. 3. Effects of BL-1249 on pore K<sup>+</sup> occupancy and permeation.** (A) Ion occupancy (frequency/μs) of K<sup>+</sup> binding sites (S0 - S6) obtained from permeation MD simulations of

TRAAK  $\pm$  BL-1249, with BL-1249 adopting the identical position in TREK-2 (Fig. 2G), i.e. the negatively charged tetrazole ring (blue) in close proximity to the S6  $K^+$  ion. Coordinates were saved every 40 ps. Black arrow points to the increase in S6  $K^+$  occupancy. (B) Fold change in ion occupancy for S0 - S6 sites. (C) Bars represent permeation events/ $\mu$ s from independent 200 ns MD simulations without ( $n = 50$ ) and with BL-1249 ( $n = 30$ ). (D) Single channel TREK-2 currents recorded at +80 mV from i-o patches before (basal) and after 3  $\mu$ M BL-1249 with arrows pointing to expanded scales of framed sections. Lower middle panel depicts current amplitude histograms  $\pm$  3  $\mu$ M BL-1249 from i-o patches with  $\leq 2$  active channels (note the righthand peak represents the amplitude of two BL-1249-activated channels). Dotted lines indicate the single channel amplitude maxima  $\pm$  BL-1249. (E) Paired single channel current amplitudes before and after 3  $\mu$ M BL-1249 ( $n = 7$ ). (F) Fold activation of TALK-2 currents in i-o patches with 50  $\mu$ M BL-1249 or 1 mM 2-APB applied at the indicated  $pH_i$  values.




Fig. 4. NCA binding sites and common pharmacophore.

**Fig. 4. NCA binding sites and common pharmacophore.** (A)  $EC_{50}$  values (at +40 mV) for TREK-1 activation with compounds described as activators of either  $K_{2P}$ , hERG or  $BK_{Ca}$  channels. Competitive antagonism is seen in presence of  $QA_L^+$  (either THexA or TPenA which produce ~70 - 80 % inhibition of respective basal  $K^+$  currents). (B) Terfenadine inhibition of hERG channels  $\pm$  10  $\mu$ M PD-118057. (C) Structure of the hERG channel (PDB ID: 5VA1) with the pore region expanded. This region was used for molecular docking and MD simulations to obtain the favoured binding pose of PD-118057 (orange). Terfenadine interacting residues are highlighted. Note the carboxylate group (red) interacts with a  $K^+$  ion below the SF (see also fig. S7D); bar chart below represents fold activation of hERG tail currents at -100 mV with 10  $\mu$ M of the indicated compounds. (D) Similar to (C) but for the  $BK_{Ca}$  channel (PDB ID: 5TJI) showing the favoured binding pose of NS11021 (orange) where the tetrazole group (red) interacts with a  $K^+$  ion below the SF and residues in proximity to NS11021 highlighted. The bar chart below shows fold activation of  $BK_{Ca}$  at +100 mV with 10  $\mu$ M of the indicated compounds (at zero  $Ca^{2+}$ ). (E) Representation of the  $K_{2P}$ , hERG and  $BK_{Ca}$  activators used to generate a common NCA pharmacophore consisting of aromatic (blue), hydrophobic (gray) and acidic (red) moieties with distances and angles as depicted.

## References and Notes:

1. S. I. V Judge, P. J. Smith, P. E. Stewart, C. T. Bever, Potassium channel blockers and openers as CNS neurologic therapeutic agents. *Recent Pat. CNS Drug Discov.* **2**, 200–28 (2007).
2. V. K. Vyas, P. Parikh, J. Ramani, M. Ghate, Medicinal Chemistry of Potassium Channel Modulators: An update of Recent Progress (2011-2017). *Curr. Med. Chem.* **25** (2018).
3. S. Hou, S. H. Heinemann, T. Hoshi, Modulation of BKCa channel gating by endogenous signaling molecules. *Physiology (Bethesda)*. **24**, 26–35 (2009).
4. M. I. Niemeyer, L. P. Cid, W. Gonzalez, F. V. Sepúlveda, Gating, Regulation, and Structure in K<sub>2</sub>P K<sup>+</sup> Channels: In Varietate Concordia? *Mol. Pharmacol.* **90**, 309–317 (2016).
5. F. V. Sepúlveda, L. Pablo Cid, J. Teulon, M. I. Niemeyer, Molecular Aspects of Structure, Gating, and Physiology of pH-Sensitive Background K<sub>2</sub>P and Kir K<sup>+</sup>-Transport Channels. *Physiol. Rev.* **95**, 179–217 (2015).
6. G. Yellen, The voltage-gated potassium channels and their relatives. *Nature*. **419**, 35–42 (2002).
7. P. L. Piechotta *et al.*, The pore structure and gating mechanism of K<sub>2</sub>P channels. *EMBO J.* **30**, 3607–19 (2011).
8. S. N. Bagriantsev, R. Peyronnet, K. A. Clark, E. Honoré, D. L. Minor, Multiple modalities converge on a common gate to control K<sub>2</sub>P channel function. *EMBO J.* **30**, 3594–606 (2011).
9. C. M. Wilkens, R. W. Aldrich, State-independent block of BK channels by an intracellular quaternary ammonium. *J. Gen. Physiol.* **128**, 347–364 (2006).
10. Y. Zhou, X.-M. Xia, C. J. Lingle, Cysteine scanning and modification reveal major differences between BK channels and Kv channels in the inner pore region. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 12161–12166 (2011).
11. P. L. Smith, T. Baukrowitz, G. Yellen, The inward rectification mechanism of the HERG cardiac potassium channel. *Nature*. **379**, 833–836 (1996).

12. J. I. Vandenberg, E. Perozo, T. W. Allen, Towards a Structural View of Drug Binding to hERG K<sup>+</sup> Channels. *Trends Pharmacol. Sci.* **38**, 899–907 (2017).
13. L. Pope *et al.*, *ACS Chem. Neurosci.*, in press, doi:10.1021/acchemneuro.8b00337.
14. J. Zhou *et al.*, Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. *Mol. Pharmacol.* **68**, 876–884 (2005).
15. B. H. Bentzen *et al.*, The small molecule NS11021 is a potent and specific activator of Ca<sup>2+</sup>-activated big-conductance K<sup>+</sup> channels. *Mol. Pharmacol.* **72**, 1033–1044 (2007).
16. M. J. Linares, D. Burdette, T. Wagner, P. J. Focia, A. Gross, Structures of KcsA in complex with symmetrical quaternary ammonium compounds reveal a hydrophobic binding site. *Biochemistry.* **53**, 5365–5373 (2014).
17. M. Schewe *et al.*, A Non-canonical Voltage-Sensing Mechanism Controls Gating in K2P K(+) Channels. *Cell.* **164**, 937–49 (2016).
18. J. G. McCoy, C. M. Nimigean, Structural correlates of selectivity and inactivation in potassium channels. *Biochim. Biophys. Acta.* **1818**, 272–285 (2012).
19. Y. Y. Dong *et al.*, K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac. *Science.* **347**, 1256–1259 (2015).
20. M. Rapedius *et al.*, State-independent intracellular access of quaternary ammonium blockers to the pore of TREK-1. *Channels.* **6**, 473–478 (2012).
21. R.-G. Zhuo *et al.*, Intersubunit Concerted Cooperative and cis-Type Mechanisms Modulate Allosteric Gating in Two-Pore-Domain Potassium Channel TREK-2. *Front. Cell. Neurosci.* **10**, 127 (2016).
22. M. Lolicato *et al.*, K2P2.1 (TREK-1)–activator complexes reveal a cryptic selectivity filter binding site. *Nature.* **547**, 364–368 (2017).
23. W. Kopec *et al.*, Direct knock-on of desolvated ions governs strict ion selectivity in K<sup>+</sup> channels. *Nat. Chem.* **10**, 813–820 (2018).

24. M. V Clausen, V. Jarerattanachat, E. P. Carpenter, M. S. P. Sansom, S. J. Tucker, Asymmetric mechanosensitivity in a eukaryotic ion channel. *Proc. Natl. Acad. Sci. U. S. A.* **114**, E8343–E8351 (2017).
25. D. Kang, C. Choe, D. Kim, Thermosensitivity of the two-pore domain K<sup>+</sup> channels TREK-2 and TRAAK. *J. Physiol.* **564**, 103–116 (2005).
26. M. Zhou, R. MacKinnon, A mutant KcsA K(+) channel with altered conduction properties and selectivity filter ion distribution. *J. Mol. Biol.* **338**, 839–846 (2004).
27. S. N. Bagriantsev *et al.*, A high-throughput functional screen identifies small molecule regulators of temperature- and mechano-sensitive K<sub>2</sub>P channels. *ACS Chem. Biol.* **8**, 1841–51 (2013).
28. L. Minieri *et al.*, The inhibitor of volume-regulated anion channels DCPIB activates TREK potassium channels in cultured astrocytes. *Br. J. Pharmacol.* **168**, 1240–1254 (2013).
29. E. Gordon *et al.*, 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. *Mol. Pharmacol.* **73**, 639–651 (2008).
30. R. S. Hansen *et al.*, Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. *Mol. Pharmacol.* **70**, 1319–1329 (2006).
31. S. Roy *et al.*, Structure-activity relationships of a novel group of large-conductance Ca(2<sup>+</sup>)-activated K(+) (BK) channel modulators: the GoSlo-SR family. *ChemMedChem.* **7**, 1763–9 (2012).
32. W. Wang, R. MacKinnon, Cryo-EM Structure of the Open Human Ether-a-go-go-Related K(+) Channel hERG. *Cell.* **169**, 422–430.e10 (2017).
33. V. Pau, Y. Zhou, Y. Ramu, Y. Xu, Z. Lu, Crystal structure of an inactivated mutant mammalian voltage-gated K(+) channel. *Nat. Struct. Mol. Biol.* **24**, 857–865 (2017).
34. H. Yang, G. Zhang, J. Cui, BK channels: multiple sensors, one activation gate. *Front. Physiol.* **6**, 29 (2015).

## **Acknowledgments:**

We thank Florian Lesage for the THIK-1 and THIK-2 K<sub>2P</sub> channel clones. We also thank Mark A. Hollywood for providing the BK<sub>Ca</sub> activator GoSlo-SR-5-6. Further we thank Jana Kusch for initially testing the BL-1249 effect on CNGA1 channels. We thank all members of our respective laboratories for technical support and comments on the manuscript.

**Funding:** T.B. and B.L.d.G. were supported by the DFG, B.F. was supported by the DFG (SFB746, TRR 152, EXC 294, 2189), S.J.T. and E.P.C were supported by a BBSRC Industrial Partnership Award (BB/N009274/1) and LJC by a Wellcome Trust (OXION) PhD studentship. A.M. was funded by the EPSRC Life Sciences Interface Doctoral Training Centre, A.C.W.P. and E.P.C. are members of the SGC (Charity ref: 1097737) funded by AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, Genome Canada, Janssen, Merck KGaA, MSD, Novartis, the Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP and Takeda, as well as the Innovative Medicines Initiative Joint Undertaking ULTRA-DD grant 115766 and the Wellcome Trust106169/Z/14/Z. D.C.P. was an employee of Pfizer (present address: Curadev Pharma Ltd., Sandwich Kent, UK). We thank Diamond Light Source Ltd and their staff for access to the macromolecular crystallography beamlines. We also acknowledge the North-German Supercomputing Alliance (HLRN) for providing High Performance Computing (HPC) resources that have contributed to the research results reported in this paper.

**Author contributions:** M.S. and T.B. conceived the study and designed the electrophysiological experiments. M.S., Ü.M., F.S. and M.T. performed all inside-out patch-clamp experiments in *Xenopus* oocytes. M.S. and T.B. analyzed the data. M.M. designed K<sup>+</sup> channel mutations. C.C. performed whole-cell recordings in CHO cells and analyzed the data together with B.F. Single channel recordings in *Xenopus* oocytes were carried out and analyzed by K.V. and A.K.K. supervised by N.D. Single channel recordings in HEK293 cells were performed and analyzed by L.J.C. supervised by S.J.T. A.M. purified TREK-2 and co-crystallized TREK-2 with BL-1249<sup>Br</sup>. A.M. and A.C.W.P. obtained and analysed the X-ray data supervised by E.P.C and S.J.T. D.P. synthesized the brominated BL-1249. H.B. synthesized ML67-33 supervised by M.N. H.S. designed, performed and analyzed all molecular dockings and MD simulations with critical comments of B.L.d.G. W.G. calculated and analyzed the NCA pharmacophore together with M.S. and N.D. M.S. and M.M. prepared and edited all figures. T.B. M.S., B.F., E.P.C and S.J.T. contributed to the writing and editing of the manuscript, and approved the manuscript. **Competing interests:** Authors declare no

competing interests. **Data and materials availability:** All data is available in the main text or the supplementary materials. Correspondence and requests for materials should be addressed to M.S. (m.schewe@physiologie.uni-kiel.de) or T.B. (t.baukrowitz@physiologie.uni-kiel.de).

**Supplementary Materials:**

**Materials and Methods**

**Figs. S1 to S9**

**Tables S1 to S3**

**References (35-67)**

## Supplementary Materials for: A Pharmacological Master Key Mechanism that Unlocks the Selectivity Filter Gate in K<sup>+</sup> Channels

### Materials and Methods

#### Molecular Biology and Experimental Electrophysiology

Rat K<sub>2P</sub> TREK-1 (Genbank accession number: NM\_172042), human K<sub>2P</sub> TREK-2 (NM\_021161), human K<sub>2P</sub> TRAAK (NM\_033310), human K<sub>2P</sub> TALK-1 (NM\_032115), human K<sub>2P</sub> TALK-2 (EU978944), human K<sub>2P</sub> THIK-1 (NM\_022054), human K<sub>2P</sub> THIK-2\* Mbr based on (NM\_022055; Mutations R11A, R12A, R14A, R15A, R16A and A155P), human ERG (EF00514521), human K<sub>v</sub>1.1 (NM\_004974), human K<sub>v</sub>1.5 (NM\_002234), human K<sub>v</sub>3.1 (NM\_001112741), rat K<sub>ir</sub>1.1 (NM\_017023), rat K<sub>ir</sub>2.1 (NM\_008425), mouse BK<sub>Ca</sub> Δ0-65 (NM\_001253378) and bovine CNGA1 (NM\_174278.2) were used in this study.

**Inside-out macropatch measurements.** For K<sup>+</sup> channels expressed in *Xenopus laevis* oocytes the respective K<sup>+</sup> channel subtype coding sequences were subcloned into the pBF, pFAW or pSGEM vectors. Point mutations were introduced by site-directed mutagenesis using custom primers containing the desired mutation and finally verified by sequencing. Vector DNA was linearized with NheI or MluI and mRNA synthesized *in vitro* using the SP6 or T7 AmpliCap Max High Yield Message Maker Kit (Cellscript, Madison, USA) and stored in stock solutions at -80 °C. *Xenopus* oocytes were surgically removed from anesthetized adult females, treated with type II collagenase (Sigma-Aldrich) and manually defolliculated. About 50 nl of a solution containing the K<sup>+</sup> channel specific cRNA was injected into Dumont stage V - VI oocytes and subsequently incubated at 17 °C in a solution containing (mM): 54 NaCl, 30 KCl, 2.4 NaHCO<sub>3</sub>, 0.82 MgSO<sub>4</sub> x 7 H<sub>2</sub>O, 0.41 CaCl<sub>2</sub>, 0.33 Ca(NO<sub>3</sub>)<sub>2</sub> x 4 H<sub>2</sub>O and 7.5 TRIS (pH 7.4 adjusted with NaOH/HCl) for 1 - 7 days before use. Electrophysiological recording: Macro patch recordings in inside-out configuration under voltage-clamp conditions were performed at room temperature (22 - 24 °C). Patch pipettes were made from thick-walled borosilicate glass, had resistances of 0.2 - 0.5 MΩ (tip diameter of 10 - 25 μm) and filled with a pipette solution (in mM): 120 KCl, 10 HEPES and 3.6 CaCl<sub>2</sub> (pH 7.4 adjusted with KOH/HCl). Intracellular bath solutions and compounds were applied to the cytoplasmic side of excised macro patches for the various K<sup>+</sup> channels via a gravity flow multi-barrel pipette system. Intracellular solution had the following composition (in mM): 120 KCl, 10 HEPES, 2 EGTA and 1 Pyrophosphate (pH adjusted with KOH/HCl). These patch pipette and intracellular solutions were used for recordings of K<sub>2P</sub>, K<sub>v</sub> and hERG

channels (pH 8.0 for measurements of TREK-1/-2 WT and mutant channels to avoid pH activation; otherwise pH 7.4). For  $K_{ir}$  channels phosphatidylinositol-4,5-bisphosphate ( $PIP_2$ ) was added to a final concentration of 10  $\mu$ M to the intracellular bath solution to avoid spontaneous run down. For CNGA1 channels the pipette and intracellular bath solution were (in mM): 150 KCl, 5 HEPES, 1 EGTA (pH 7.4 adjusted with KOH/HCl). For  $BK_{Ca}$  channels the pipette and intracellular bath solution were (in mM): 120  $KNO_3$ , 10 HEPES, 10 EGTA (pH 7.4 adjusted with KOH/ $HNO_3$ ). In other intracellular bath solutions,  $K^+$  was replaced by  $Rb^+$  either with  $Cl^-$  or  $NO_3^-$  as the counterion (pH 7.4 adjusted with  $RbOH/HCl$  or  $RbOH/HNO_3$  respectively). Currents were recorded with an EPC10 amplifier (HEKA electronics, Germany) and sampled at 10 kHz or higher and filtered with 3 kHz (-3 dB) or higher as appropriate for sampling rate.

Chemical Compounds: Tetra-ethyl-ammonium chloride (TEA-Cl), tetra-pentyl-ammonium chloride (TPenA-Cl), tetra-hexyl-ammonium chloride (THexA-Cl), Guanosine-3':5'-cyclic monophosphate (cGMP), (5,6,7,8-Tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine (BL-1249), 2-aminoethoxydiphenyl borate (2-APB), losartan potassium, olmesartan, valsartan (Sigma-Aldrich), 2-[[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino]benzoic acid (PD-118057), *N*-[4-Bromo-2-(1*H*-tetrazol-5-yl-phenyl)]-*N'*-[3-(trifluoromethyl)phenyl]-urea (NS3623), *N'*-[3,5-Bis(trifluoromethyl)phenyl]-*N*-[4-bromo-2-(2*H*-tetrazol-5-yl-phenyl)]thiourea (NS11021), 4-[(2-Butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1*H*-inden-5-yl)oxy]butanoic acid (DCPIB) and  $\alpha$ -[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol (terfenadine) (Tocris Bioscience), 8-(tributylammonium)octyl methanethiosulfonate bromide (MTS-TBAO-Br) (Toronto Research Chemicals, Inc.), phosphatidylinositol-4,5-bisphosphate ( $PIP_2$ ) (Santa Cruz Biotechnology, Inc.), 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1*H*-isoindol-5-ylamino]-nicotinic acid (PD-307243), (*N*-[(2,4-dichlorophenyl)methyl]-4-(methanesulfonamido)benzamide) (ML335) (ChemBridge Corp.), (sodium 1-amino-4-((3-trifluoromethylphenyl)amino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) (GoSlo-SR-5-6) (provided by Mark Hollywood) and 2,7-Dichloro-9,9-dimethyl-10-[2-(1*H*-1,2,3,4-tetrazol-5-yl)ethyl]-4a,9a-dihydroacridine (ML67-33) (synthesized according to procedure previously described<sup>1</sup>) were stored as stocks (10 - 100 mM) at -80 °C and diluted in intracellular solution prior to the measurements or were added directly to a final concentration in intracellular solutions.

Data acquisition: Data analysis and statistics were done with Microsoft Excel 2011 (Microsoft Corporation, USA) and Igor Pro 6.34 software (Wavemetrics Inc., USA). The relative steady-

state level of  $K^+$  channel activation for the different activators was fitted with the Hill equation in the following form:  $\text{base} + (\text{max} - \text{base}) / (1 + (x_{\text{half}}/x)^h)$ , where base = basal current, max = maximal activated current, x = compound concentration, xhalf = value of concentration for half-maximal occupancy of the compound binding site and h = Hill coefficient. Graphing was performed with Canvas X (ACD Systems of America, Inc., USA).

**Single channel recordings.** For single channel recordings of TREK-2  $K_{2P}$  channels, HEK293 cells were transfected with human TREK-2 in pFAW (50 - 100 ng) using Fugene (Promega) and studied 18 - 24 h post transfection. The human TREK-2 sequence is the M3 variant, engineered to remove the multiple products of alternative translation initiation (35). Pipette resistance was 6 - 10 M $\Omega$ . Pipette and intracellular bath solution contained (in mM): 120 KCl, 10 HEPES and 2 EGTA (pH 7.2 adjusted with KOH/HCl). Excised patch recordings were made with an Axopatch 200B amplifier and Digidata 1550B A/D-Converter (Axon Instruments) with a 10 kHz bandwidth and a sampling rate of 50 kHz at room temperature (21 - 24 °C). 3  $\mu$ M BL-1249 was applied via the intracellular bath solution. Data were analyzed using the single channel analysis tools: WinEDR ([http://spider.science.strath.ac.uk/sipbs/software\\_ses.htm](http://spider.science.strath.ac.uk/sipbs/software_ses.htm)). For single channel recordings of TREK-1  $K_{2P}$  channels expressed in *Xenopus laevis* oocytes pipettes had a tip resistance of 5.0 - 10.0 M $\Omega$  when filled with the pipette solution containing (in mM): 120 KCl, 10 HEPES, 3.6 CaCl<sub>2</sub> (pH 7.4 adjusted with KOH/HCl). Single channel currents were recorded with a sampling rate of 15 kHz with analog filter set to 5 kHz. Single channel amplitudes were evaluated from raw data histograms and kinetics were analyzed using the ClampFit10 software (Molecular Devices). For illustration the data were subsequently filtered with a -3 dB, 8-pole Bessel filter at 2 kHz using ClampFit10.

**Whole-cell recordings.** For whole-cell recordings of BK<sub>Ca</sub> channels, Chinese hamster ovary (CHO) cells were transiently transfected with cDNA coding for the mouse BK<sub>Ca</sub> channel alpha subunit and GFP. Cells were incubated at 37 °C and 5 % CO<sub>2</sub> and measured 2 - 4 days after transfection. Electrophysiological recording: Whole-cell patch-clamp recordings were performed at room temperature (21 - 24 °C) using a HEKA EPC10 amplifier. Currents were low-pass filtered at 3-10 kHz and sampled at 20 kHz. Leak currents were subtracted using a P/4 leak subtraction protocol with holding potential of -90 mV and voltage steps opposite in polarity to those in experimental protocol. Serial resistance was 30 - 70 % compensated using the internal compensation circuitry. The extracellular solution contained (in mM): 5.8 KCl, 144 NaCl, 0.9 MgCl<sub>2</sub>, 1.3 CaCl<sub>2</sub>, 0.7 NaH<sub>2</sub>PO<sub>4</sub>, 5.6 D-Glc and 10 HEPES (pH 7.4 adjusted with KOH/HCl). Recording pipettes pulled from quartz glass had resistance of 2-3.5 M $\Omega$

when filled with internal solution containing (in mM): 139.5 KCl, 3.5 MgCl<sub>2</sub>, 2 DiBrBAPTA, 5 HEPES, 2.5 Na<sub>2</sub>ATP and 0.1 Na<sub>3</sub>GTP (pH 7.3). For some experiments THexA (50 μM) was added to the internal solution. Steady state activation of BK<sub>Ca</sub> channels was determined using test pulses ranging from -50 mV to +200 mV (with 10 mV increments), followed by a repolarization step to 0 mV. Conductance-voltage relations were determined from tail current amplitudes measured 0.5 ms after repolarization to a membrane potential of 0 mV and normalized to the maximum. For fitting, a Boltzmann equation was used in the form:  $g/g_{max} = g_{max}/(1 + \exp((V_h - V_m)/k))$ , where  $V_h$  is the voltage required for half-maximal activation and  $k$  the slope factor. All the chemicals except DiBrBAPTA (Alfa Aesar) were purchased from Sigma-Aldrich. Final concentration of the activator NS11021 was 30 μM.

### **Crystallography**

**Purification and co-crystallization of TREK-2 with brominated BL-1249.** TREK-2 protein was purified as previously described (19). For co-crystallization, brominated BL-1249 (BL-1249<sup>Br</sup>) dissolved in DMSO was added to purified TREK-2 giving a solution containing 10 mg/ml TREK-2, 5 mM BL-1249<sup>Br</sup>, 5 % DMSO, 50 mM HEPES (pH 7.5), 200 mM KCl, 0.12 % OGNG, 0.012 % cholesteryl hemi-succinate (CHS), which was incubated on ice for 7 hours. Co-crystals of TREK-2 and BL-1249<sup>Br</sup> were obtained at 4 °C using sitting drops comprising 100 nl of protein/ligand solution and 50 nl of a reservoir solution containing 0.1 M Tris pH 7.5, 1 mM CdCl<sub>2</sub> and 29 % (v/v) polyethylene glycol (PEG)400, using a Mosquito crystallization robot (TTP Labtech). The brominated form of BL-1249 used in this study produces  $94 \pm 2$  % ( $n = 6$ ) of the peak whole-cell current of unmodified BL-1249 when applied at a concentration of 30 μM on TREK-2 channels expressed in *Xenopus* oocytes.

**Anomalous diffraction data collection and location of bromine positions.** Prior to mounting, crystals were incubated with an additional 7.5 mM BL-1249<sup>Br</sup> for 2 hours. The concentration of PEG400 was increased to 40 % in a step-wise manner prior to flash cooling. 920° of data were collected close to the Br K-edge ( $\lambda = 0.905$  Å) on beamline I03 at the Diamond Light Source Ltd. Data were indexed and reduced using XDS (36) and scaled with XSCALE/AIMLESS (37). The final dataset has a nominal resolution of 4.1 Å (Mn I/sd  $I > 2.0$ ) but displayed moderate anisotropy (3.8 Å x 4.1 Å x 4.9 Å - for details see table S1). Significant anomalous signal was detectable to around 6.5 Å ( $CC_{anom} > 0.15$ ). The structure was solved by molecular replacement using PHASER (38) with the coordinates of the down-state TREK-2 structure as the initial model (PDB ID: 4XDJ). The crystals belong to space group  $P2_1$  and the asymmetric unit contained two TREK-2 dimers. The positions of the

bromine atoms and cadmium ions were located by calculating anomalous difference Fourier maps at 6 Å resolution. The two highest peaks (10.7 - 11.7  $\sigma$ ) in the map correspond to two cadmium ions that derived from the crystallization solution. The putative bromine atoms were the next highest peaks in the map (4.1 - 6.2  $\sigma$ ). Two Br peaks could be located for each TREK-2 dimer with one site stronger than the other (AB dimer: 6.24/4.59  $\sigma$ ; CD dimer 4.11/4.97  $\sigma$ ). Regular crystallographic refinement with BUSTER (39) did not show any conventional electron density for either the bromine atoms or BL-1249 itself suggesting low occupancy and multiple binding modes. Given the lack of any conventional electron density, no attempt was made to model or refine a BL-1249<sup>Br</sup>-TREK-2 complex structure based on the X-ray data. The positions of the bromine atoms shown in Fig. 2A and fig. S3 are based solely on real-space fitting to the peaks in the 6 Å anomalous difference map.

### **Molecular Dynamics Simulations**

Molecular docking and MD simulations of the TREK-2 and TRAAK channels were based on their respective down-state crystal structures (PDB ID: 4XDJ (19) and PDB ID: 4I9W (40)). The hERG and BK<sub>Ca</sub> (Slo1) structures were based on their respective cryo-EM structures (PDB ID: 5VA1 (32) and PDB ID: 5TJI (41)), where only the transmembrane domains M5 to M6 of hERG and BK<sub>Ca</sub> channels were selected and simulated (residues 545 - 669 for hERG, residues 219 - 318 for BK<sub>Ca</sub>). Missing loops in the cryo-EM structure of the hERG channel (residues 578 - 582, 598 - 602 in chains A to D) as well as missing side chains were built with the program MODELLER (42). We determined and evaluated the most probable binding poses for BL-1249, ML67-33, DCPIB, PD-307243, PD-118057, NS3623 and NS11021 with TREK-2, PD-118057 and PD-307243 with hERG as well as NS11021 and GoSlo-SR-5-6 with BK<sub>Ca</sub> by a combination of X-ray crystallography, mutagenesis, molecular docking and molecular dynamics simulations. The procedures were performed as follows.

**Binding pose of BL-1249 with TREK-2.** Based on the results of a competition assay of BL-1249 with QA<sub>L</sub><sup>+</sup> blockers, we expected that BL-1249 binds within the pore cavity close to the known binding sites for QA<sub>L</sub><sup>+</sup> blockers in other K<sup>+</sup> channels. First, we used molecular docking to explore possible binding poses of BL-1249<sup>Br</sup> with the down-state conformation of TREK-2, where the residues around the fenestration site were defined as the center of the docking pocket. A receptor grid was calculated for TREK-2 with a box size of 10 Å x 10 Å x 10 Å. Docking of the compounds into the pockets were subsequently carried out. 5 docking poses with highest scores were selected and further used as the initial structures in the first set of MD simulations. For each docking pose, 10 runs of 20 ns

simulations were performed. We evaluated all possible binding poses sampled during the MD simulations and discarded those poses, which did not show interactions with residues L320 and P198 as suggested by mutagenesis studies, or significantly violated the coordinates of bromine in BL-1249<sup>Br</sup> bound to the TREK-2 channel as provided by the low-resolution X-ray data. At the end, two binding modes remained, both of which were stable in several 100 ns MD simulations. Although mutagenesis and low-resolution X-ray data did not allow us to distinguish between both binding modes, only one was chosen as the other was predicted to block the ion conduction pathway. Furthermore, only in this most binding mode were two BL-1249<sup>Br</sup> molecules stable within one TREK-2 channel, which agreed well with the experimental data.

**Binding poses of ML67-33, DCPIB and PD-307243 with TREK-2.** Competition assays revealed that ML67-33, DCPIB, and PD-307243 bind in the same binding pocket of the TREK-2 channel as BL-1249. Therefore, as a first step a receptor grid was recalculated for TREK-2 and centered in the binding pose of BL-1249<sup>Br</sup> with a box size of 10 Å x 10 Å x 10 Å. Docking of the compounds into the pockets was subsequently carried out and 5 poses for each ligand with highest docking scores were retained. The stability of each docking pose was evaluated and the binding poses were refined by 10 runs of 100 ns MD simulations. The most stable binding poses during the MD simulations were selected as the most probable binding modes.

**Binding pose of PD-118057 with TREK-2.** Due to remarkable structural similarities between PD-118057 and PD-307243, PD-118057 was manually aligned to the previously determined binding pose of PD-307243 in TREK-2. The pose of PD-118057 was further refined by 5 runs of 100 ns MD simulations. The most stable binding pose during the MD simulations was selected as the most probable binding mode.

**Binding poses of NS3623 and NS11021 with TREK-2.** Due to remarkable structural similarities between both NS ligands and BL-1249, NS3623 and NS11021 were manually aligned to the previously determined binding pose of BL-1249 in TREK-2. The poses of NS3623 and NS11021 were further refined by 5 runs of 100 ns MD simulations, respectively. The most stable binding poses during the MD simulations were selected as the most probable binding modes.

**Binding poses of PD-118057 with hERG.** Previous mutagenesis studies revealed a high-affinity drug binding site in the hERG channel pore (43-45) involving several residues (T623, S624, V625, G648, Y652 and F656) located near the central pore cavity (32). Given that this site also accommodates terfenadine and PD-118057 competes with terfenadine for binding, as

starting point for the molecular docking, a receptor grid was calculated for the hERG channel with a box size of 10 Å x 10 Å x 10 Å, where these identified residues were defined as the centre of the docking pocket. Docking of the compounds into the pocket was subsequently carried out. 5 docking poses with highest scores were selected and further used as the initial structures in MD simulations. The stability of each docking pose was evaluated, and the binding poses were refined by 10 runs of 100 ns MD simulations. The most stable binding poses during the MD simulations were selected as the most probable binding modes.

**Binding poses of GoSlo-SR-5-6 and NS11021 with BK<sub>Ca</sub>.** Competition assays revealed that activation of the BK<sub>Ca</sub> channel by GoSlo-SR-5-6 and NS11021 is antagonized by THexA, suggesting that the particularly large pore cavity below the selectivity filter could potentially accommodate these small molecule activators. Therefore, for the molecular docking a receptor grid with a larger box size of 15 Å x 15 Å x 15 Å that covers the pore cavity was calculated for the BK<sub>Ca</sub> channel, where we chose the first residue of the selectivity filter (T276) as the centre of the box. Docking of the compounds into the pockets was subsequently performed. Only one docking pose for GoSlo-SR-5-6 and NS11021, respectively, was obtained with the negatively charged groups pointing to the center of the cavity. The stability of the docking poses was evaluated, and the binding poses were further refined by 5 runs of 100 ns MD simulations.

**Methods for molecular docking.** Molecular docking simulations of BL-1249<sup>Br</sup>, ML67-33, DCPIB, PD-307243, PD-118057, NS3623 and NS11021 with the TREK-2 channel, of PD-118057 and PD-307243 with the hERG channel as well as of NS11021 and GoSlo-SR-5-6 with the BK<sub>Ca</sub> channel were carried out with Glide from the Schrödinger package (46). Docking of the compounds into the channel pockets was performed with Glide SP (standard precision) from Schrödinger.

**Molecular dynamics (MD) simulations.** For the MD simulations, all ion channels were embedded in a hydrated 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) lipid bilayer at an ionic concentration of 0.6 M KCl. We used the AMBER99sb\* force field (47) and the TIP3P water model (48) for the equilibration and production simulations of the proteins. Parameters for ions and lipids were derived from (49, 50). All ligands were optimized and their electrostatic potentials were calculated at the Hartree-Fock/6-31G\* level using the program Gaussian09. The generalized amber force field (GAFF) (51) topologies of the ligands were generated with the Antechamber software (52) using partial charges from quantum mechanics calculations according to the restrained electrostatic potential (RESP) approach (53). Tetrazole and carboxylic acid have pK<sub>a</sub> values of about 4.5 - 4.9 (54), indicating that both

groups are non-protonated and negatively charged at pH 7.0. The sulfonate group in GoSlo-SR-5-6 activators is strongly acidic and negatively charged at pH 7.0. Protonation states of all protein residues were chosen to correspond to a pH value of 7.0. MD simulations were carried out with GROMACS 5.0 and 5.1 (55, 56). Short-range electrostatic interactions were calculated with a cutoff of 1.0 nm, whereas long-range electrostatic interactions were treated by the particle mesh Ewald method (57, 58). The cutoff for van-der-Waals interactions were set to 1.0 nm. The simulations were performed at 300 K with a velocity rescaling thermostat (59). The pressure was kept at 1 bar by means of a semi-isotropic Parrinello-Rahman barostat (60, 61). All bonds were constrained with the LINCS algorithm (62). For the computational electrophysiology study (63), the equilibrated system of BL-1249<sup>Br</sup> bound TRAAK was duplicated along the z direction and transmembrane potential gradients were generated by introducing a charge difference of 2 K<sup>+</sup> ions between the two compartments separated by the two lipid bilayers. During the MD simulations, the number of the ions was kept constant by an additional algorithm (63). The resulting membrane potential can be calculated by double-integration of the charge distribution using the Poisson equation as implemented in the GROMACS tool *g\_potential* (64). In the computational electrophysiology simulations of BL-bound TRAAK, a K0KK0K (S0, S1, S2, S3, S4, S5) ionic configuration was employed as the starting structure, as it was the largest populated ionic configuration in MD simulations of apo-TRAAK (17) and KcsA (65) using the same method. This ionic configuration is consistent with a direct knock-on mechanism of potassium conduction. Notably, our previous study revealed that the permeation mechanism does not depend on the exact starting configuration (65). In order to prevent spontaneous dissociation of ligand during the permeation simulation, we restrained the position of bromine of BL-1249<sup>Br</sup> at the crystallographically determined position with a harmonic force constant of 1000 kJ mol<sup>-1</sup> nm<sup>-2</sup>. During the simulations a permeation event was counted when an ion moved from the cavity to the filter, and another ion left the S0 position. The computational electrophysiology simulations of apo-WT TRAAK were described in previous work (17).

### **Molecular Pharmacophore Modeling**

The required interactions between a K<sub>2P</sub> channel and a ligand depend on structural and chemical complementarity among them. We used PHASE from Schrödinger molecular modeling Suite (66) to generate a pharmacophore. PHASE categorizes the chemical characteristics of the ligands as hydrogen bond acceptors (A), hydrogen bond donors (D), hydrophobic groups (H), negatively charged groups (N), positively charged groups (P) and

aromatic rings (R). In order to develop a common pharmacophore, PHASE evaluates the n-point pharmacophores resulting from the conformational sets of active compounds and then detects all three-dimensional arrangements with pharmacophore qualities common for these compounds (67).

### **Statistical analyses**

All values are represented as mean  $\pm$  S.E.M. with n indicating the number of individual executed experiments. Error bars in all figures represent S.E.M. values with numbers at base (n) indicating the definite number of executed experiments. A Shapiro-Wilk test or Kolmogorow-Smirnow test was used to determine whether measurements were normally distributed. Statistical significance between two groups was validated using the Student's *t*-test or Wilcoxon rank test after *f*-test application. Asterisks indicate the following significance: \*  $\leq 0.05$ , \*\*  $\leq 0.01$  and \*\*\*  $\leq 0.001$ . Zero current level was indicated using dotted lines in all figures.




Fig. S1. Activation of K<sup>+</sup> channels (K<sub>2P</sub> and BK<sub>Ca</sub>) and competitive antagonism by QA<sub>L</sub><sup>+</sup>.

**Fig. S1. Activation of K<sup>+</sup> channels (K<sub>2P</sub> and BK<sub>Ca</sub>) and competitive antagonism by QA<sub>L</sub><sup>+</sup>.** (A) Left: TREK-1 currents at +40 mV upon application of 1 mM TPenA (full inhibition) and 5  $\mu$ M THexA in the absence (basal current) and presence of 10  $\mu$ M BL-1249; right: bars represent THexA inhibition  $\pm$  BL-1249 from experiments as shown in the left panel. (B) Left: TALK-1 currents evoked by voltage ramps from -80 mV to +80 mV (black trace; basal) and inhibition by 10  $\mu$ M THexA (green trace); middle: TALK-1 currents activated by 500  $\mu$ M BL-1249 (pink) and subsequent inhibition by 10  $\mu$ M THexA (green); right: bars represent THexA inhibition  $\pm$  BL-1249 from experiments as shown in the left and middle panels. (C) Current-voltage relations from BK<sub>Ca</sub> channel whole-cell tail current amplitudes ( $I/I_{max}$ ) in presence of 30  $\mu$ M NS11021, 50  $\mu$ M THexA, 30  $\mu$ M NS11021 with 50  $\mu$ M THexA, and without compounds (basal); lines represent fits to a standard Boltzmann function ( $n \geq 8$ ). (D) Bars represent EC<sub>50</sub> values  $\pm$  S.E.M. and maximal fold activation  $\pm$  S.E.M. for the indicated K<sub>2P</sub> channel upon application of BL-1249.




Fig. S2. BL-1249 fails to activate  $K^+$  channels gated at the lower helix-bundle crossing and SF-gated CNG channels.

**Fig. S2. BL-1249 fails to activate  $K^+$  channels gated at the lower helix-bundle crossing and SF-gated CNG channels.** The effect of BL-1249 on  $K^+$  channels that use the helix-bundle crossing as an activation gate (i.e.  $K_{ir}$  and  $K_v$  channels) was tested in i-o patches from channels expressed in *Xenopus* oocytes. (A) Representative  $K_{ir}1.1$  currents evoked by voltage ramps from -80 mV to +80 mV at pH 7.4 (strong  $pH_i$  activation) and pH 6.0 (weak  $pH_i$  activation) of the same patch without (basal) and with 10  $\mu$ M BL-1249 as indicated. Voltage-dependent inhibition by 10 mM TPenA is shown to demonstrate typical  $K_{ir}1.1$  activity. (B)  $K_{ir}2.1$  currents evoked by identical voltage ramps at pH 7.4 without (basal) and with 10  $\mu$ M BL-1249. Voltage-dependent inhibition by 10 mM TPenA is shown to demonstrate a typical  $K_{ir}2.1$  response. (C)  $K_v1.5$  currents evoked by voltage steps from -100 mV to +40 mV with 10 mV increments as depicted without (basal) and with 10  $\mu$ M BL-1249. Note BL-1249 causes a weak transient inhibition (similar to open channel block), but no activation is

apparent by comparing the tail current/voltage relationship (**D**)  $\pm 10 \mu\text{M}$  BL-1249 (i.e. no shift in  $V_{1/2}$  of voltage activation;  $n \geq 11$ ). (**E**)  $K_v3.1$  currents evoked by depolarization from a holding potential of  $-80 \text{ mV}$  to  $+60 \text{ mV}$  and back as indicated  $\pm 10 \mu\text{M}$  BL-1249. Note BL-1249 causes a weak transient inhibition and  $\sim 30\%$  block of the initial outward current. (**F**) The effect of  $50 \mu\text{M}$  BL-1249 on representative basal currents  $\pm 1 \text{ mM}$  cGMP for CNGA1 channels measured in i-o patches.




Fig. S3. Positions of BL-1249 Br atoms in TREK-2  $K_{2P}$  dimers based on anomalous difference peaks.

**Fig. S3. Positions of BL-1249 Br atoms in TREK-2  $K_{2P}$  dimers based on anomalous difference peaks.** (**A** and **B**) Crystallographically determined positions of bromine atoms of BL-1249<sup>Br</sup> are shown for the two dimers present in the asymmetric unit (AB/CD). A  $6 \text{ \AA}$  anomalous difference Fourier map calculated using phases from the PHASER molecular

replacement solution is contoured at  $3.3 \sigma$  (magenta mesh) and overlaid on the  $C\alpha$  trace of the partially refined PHASER solution. The highest anomalous peaks correspond to two cadmium ions ( $Cd\_1/Cd\_2$ ) from the crystallization solution bound between the cap domains of each dimer. The next highest peaks in the map represent the bromine positions ( $Br^A/Br^B/Br^C/Br^D$ ). Two perpendicular views are shown for each dimer looking from the plane of the membrane (left) and from the cytoplasmic face (right). (C) Zoomed-in view of the Br position in the AB dimer located between helix  $M2^B$  and  $M4^A$ . (D) BL-1249 dose-response curves for TREK-2 WT ( $n = 13$ ) and mutations (P198C or P198A ( $n = 14$ ), L320C or L320A ( $n = 6$ )) reducing BL-1249 activation and positioned close to the bromine. These residues are homologous to the TREK-1 mutations shown in Fig. 2D. (E) Comparison of the four crystallographically determined BL-1249 Br atoms ( $Br^A/Br^B$  (pink)  $Br^C/Br^D$  (orange)) after superposition of the two dimers and those derived from the MD simulation (brown).




Fig. S4. Specificity of the NCA  $QA_L^+$  competition assay and the BL-1249 binding site mutations.

**Fig. S4. Specificity of the NCA  $QA_L^+$  competition assay and the BL-1249 binding site mutations.** (A) Dose-response curves for activation of TREK-1 by 2-APB (left; brown curve) and ML335 (middle; orange curve)  $\pm$  80  $\mu$ M TPenA (green curve) producing  $\sim$ 71 to 77 % inhibition of the basal current at +40 mV; right: bars represent EC<sub>50</sub> values  $\pm$  S.E.M for 2-APB and ML335 activation  $\pm$  TPenA obtained from data as shown in the left and middle panels. Note ML335 and 2-APB have been shown to bind at sites outside of the inner cavity.

(B) Dose-response curves of TREK-2 channel activation by 2-APB  $\pm$  80  $\mu$ M TPenA producing  $76 \pm 2$  % inhibition of the basal current; right: bars represent  $EC_{50}$  values  $\pm$  S.E.M for 2-APB activation  $\pm$  TPenA obtained from the data as shown in the left panel. (C), (D), (E) Bars represent  $EC_{50}$  values  $\pm$  S.E.M for activation by DCPIB (C), by ML67-33 (D) and by 2-APB (E) of TREK-1 WT channels and indicated mutants that reduce BL-1249 activation (see also Fig. 2D).




Fig. S5. BL-1249 effect on TREK-1 single channel currents.

**Fig. S5. BL-1249 effect on TREK-1 single channel currents.** (A) Representative TREK-1 single channel current traces measured in the same i-o patches from *Xenopus* oocytes at +60 mV before application (upper trace; basal activity) and after application of 100  $\mu$ M BL-1249 (lower trace). (B) Example current amplitude histograms corresponding to the recordings shown in (A) and fitted with a Gaussian function to obtain the single channel amplitudes that are plotted for individual recordings before and after BL-1249 in (C).




Fig. S6. Mutations at the SF render  $K_{2P}$  channels insensitive to drug activation.

**Fig. S6. Mutations at the SF render  $K_{2P}$  channels insensitive to drug activation.** (A) Currents in i-o patches in response to voltage steps (from -100 mV to +100 mV) for WT TREK-2 channels and indicated mutants without (basal) and with 100  $\mu$ M BL-1249; from these mean data IVs  $\pm$  S.E.M are plotted. (B) Representative IVs for TREK-2 T172C and T281C currents  $\pm$  the indicated activator. (C) and (D) Bars represent fold activation  $\pm$  S.E.M at -80 mV upon application of indicated compounds (10  $\mu$ M PD-118057 and GoSlo-SR-5-6, 50  $\mu$ M NS11021 and 100  $\mu$ M BL-1249, DCPIB, NS3623, PD-307243 and ML67-33) for indicated  $K_{2P}$  channels and respective mutants (mutations substitute the conserved SF threonines that coordinate the S4 K<sup>+</sup> ion in the SF as previously reported (17)).




Fig. S7. NCAs compete with QA<sub>L</sub><sup>+</sup> in BK<sub>Ca</sub> and hERG channels and change the SF K<sup>+</sup> occupancy in hERG, BK<sub>Ca</sub> and TREK-2.

**Fig. S7. NCAs compete with QA<sub>L</sub><sup>+</sup> in BK<sub>Ca</sub> and hERG channels and change the SF K<sup>+</sup> occupancy in hERG, BK<sub>Ca</sub> and TREK-2.** (A) BK<sub>Ca</sub> currents in i-o patches evoked by voltage steps (from -80 mV to +100 mV) with THexA applied to basal currents (upper left traces), applied to Ca<sup>2+</sup> activated BK<sub>Ca</sub> currents (upper right traces); NS11021 activated BK<sub>Ca</sub> currents (lower left traces) and GoSlo-SR-5-6 activated currents (lower right traces). (B) Bars

represent the  $IC_{50}$  value  $\pm$  S.E.M. for THexA inhibition obtained from THexA dose-response curves for basal currents (indicated as dotted line) and subsequent to activation by 50  $\mu$ M NS11021, 10  $\mu$ M GoSlo-SR-5-6, 50  $\mu$ M free  $Ca^{2+}$ , 100  $\mu$ M BL-1249, 100  $\mu$ M DCPIB, 50  $\mu$ M ML67-33, 50  $\mu$ M NS3623, 10  $\mu$ M PD-118057, 50  $\mu$ M PD-307243. (C) NS3623 dose-response curves represent normalized tail currents  $\pm$  1  $\mu$ M TPenA that produced  $84 \pm 3$  % inhibition of basal currents ( $n \geq 8$ ). (D) The relative  $K^+$  occupancies for the indicated  $K^+$  sites (S2 to S6) obtained from MD simulations of hERG,  $BK_{Ca}$  and TREK-2 channels with the respective compounds docked in their favoured poses (orange) and their occupancies in the apo-structures (black lines). Note that (i) MD simulations are performed without applied voltage gradient (in contrast to Fig. 3, A and B), (ii) the  $K^+$  occupancies differ for the three apo-structures, and (iii) for  $BK_{Ca}$  and TREK-2 channels NCA binding increases the S6 occupancy (with the other changes in SF occupancy are likely promoted by the S6 increase) while in hERG channels the S5 occupancy is increased consistent with the position of the negative charge of the NCA being localized further upward towards the SF and, thus, closer to the S5  $K^+$  ion.




Fig. S8. NCA binding poses in hERG, BK<sub>Ca</sub> and TREK-2 K<sub>2P</sub> channels.

**Fig. S8. NCA binding poses in hERG, BK<sub>Ca</sub> and TREK-2 K<sub>2P</sub> channels.** (A) Structure of the hERG channel (PDB ID: 5VA1) depicted as shadow surface with the pore region highlighted (light blue) used for MD simulations to obtain the favoured binding pose of PD-307243 (orange) with the carboxylate group (red) interacting with a K<sup>+</sup> ion as illustrated. (B) Structure of the BK<sub>Ca</sub> channel (PDB ID: 5TJI) with the pore region highlighted used for MD simulations to obtain the favoured binding pose of GoSlo-SR-5-6 (orange) as depicted in the magnification with the sulphonate group (red) interacting with a K<sup>+</sup> ion in the cavity. (C) Structural representation of the favoured binding poses of the indicated compounds obtained from MD simulation performed on TREK-2; the corresponding TREK-1 residues that markedly reduce BL-1249 activation are highlighted (green). The negatively charged groups of the compounds are coloured (red) to indicate their proximity to the depicted K<sup>+</sup> ions.




Fig. S9. Negatively charged compounds that do not fit the NCA pharmacophore fail to activate TREK-1 K<sub>2P</sub>, BK<sub>Ca</sub> and hERG channels.

**Fig. S9. Tetrazole containing compounds that do not fit the NCA pharmacophore fail to activate TREK-1 K<sub>2P</sub>, BK<sub>Ca</sub> and hERG channels.** (A) Upper panel: the tetrazole and carboxylate group containing compounds losartan, olmesartan and valsartan are depicted. Although very similar in composition, they do not fit the NCA pharmacophore as shown in Fig. 4E; lower panel: TREK-1 currents of i-o patches of *Xenopus* oocytes evoked by voltage ramps from -80 mV to +80 mV without (basal) are not activated by 100 μM of the respective compounds. As a control, TREK-1 currents in the same patches were strongly activated by low pH<sub>i</sub> 5.0. (B) BK<sub>Ca</sub> currents in i-o patches evoked by voltage steps (from -80 mV to +100 mV) without (gray trace) and with 100 μM of the respective compounds. As a control, BK<sub>Ca</sub>

currents in the same patches were activated by 50  $\mu\text{M}$  free  $\text{Ca}^{2+}$  and 50  $\mu\text{M}$  of the drug NS11021. (C) hERG currents in i-o patches evoked by voltage steps (from -80 mV to +60 mV and back to -100 mV) without (gray trace) and with 100  $\mu\text{M}$  of the respective compounds. As a control, hERG currents in the same patches were activated by 10  $\mu\text{M}$  of the drug PD-118057.

**Table S1: Data collection and statistics.**

<b>Data collection</b>	<b>BL-1249<sup>Br</sup></b>
Space group	<i>P2</i> <sub>1</sub>
Cell dimensions	
<i>a</i> , <i>b</i> , <i>c</i> (Å)	89.77, 107.62, 106.69
$\alpha$ , $\beta$ , $\gamma$ (°)	90, 90.18, 90
Resolution [Å] <sup>1</sup>	75 - 3.8 (3.80 - 3.90) <sup>1</sup>
Resolution limits [Å] <sup>2</sup>	4.9, 4.1, 3.8 (4.6, 4.1, 3.8)
Nominal resolution [Å] <sup>3</sup>	4.1
CC <sub>1/2</sub>	1.000 (0.55)
CC <sub>anom</sub>	0.57
<i>R</i> <sub>meas</sub>	0.057 (3.28) <sup>1</sup>
<i>R</i> <sub>pim</sub>	0.016 (0.88)
<i>I</i> / $\sigma I$	19.7 (0.9) <sup>1</sup>
Completeness [%]	100 (100) <sup>1</sup>
Redundancy	13.3 (13.7) <sup>1</sup>

<sup>1</sup>Values in parentheses are statistics for highest resolution shell

<sup>2</sup>Anisotropic resolution limits along each of the three principal directions as defined by AIMLESS based on Mn (*I*/sd(*I*)) > 2. Values in parentheses are resolution limits in each direction based on half dataset correlation > 0.5 (CC<sub>1/2</sub>).

<sup>3</sup>Nominal resolution is defined based on overall Mn (*I*/sd (*I*)) > 2.0 CC<sub>1/2</sub> > 0.50 as estimated by AIMLESS.

**Table S2: TREK-1 K<sub>2P</sub> channel competition assay statistics.**

<b>Compound</b>	<b>EC<sub>50</sub> (μM)</b>	<b>n</b>	<b>QA<sup>+</sup> ion</b>	<b>EC<sub>50</sub> (QAL+) (μM)</b>	<b>n</b>	<b>P value</b>
BL-1249	2.64 ± 0.45	24	THexA (5 μM)	66.50 ± 1.82	8	5.78 x 10 <sup>-6</sup>
ML67-33	8.15 ± 0.75	10	TPenA (80 μM)	64.53 ± 2.54	9	3.92 x 10 <sup>-5</sup>
DCPIB	22.02 ± 2.71	12	TPenA (80 μM)	121.49 ± 4.35	19	1.49 x 10 <sup>-7</sup>
PD-118057	3.36 ± 0.76	9	TPenA (80 μM)	14.64 ± 1.19	5	7.31 x 10 <sup>-5</sup>
PD-307243	14.70 ± 0.99	9	TPenA (80 μM)	83.73 ± 4.30	12	1.62 x 10 <sup>-5</sup>
NS3623	39.21 ± 10.91	11	TPenA (80 μM)	176.60 ± 16.28	5	1.28 x 10 <sup>-4</sup>
NS11021	8.05 ± 1.29	7	TPenA (80 μM)	36.84 ± 0.85	5	6.88 x 10 <sup>-9</sup>
GoSlo-SR-5-6	5.88 ± 0.25	9	TPenA (80 μM)	82.85 ± 17.05	8	1.13 x 10 <sup>-4</sup>
2-APB	235.27 ± 20.85	28	TPenA (80 μM)	256.74 ± 19.02	21	n. s.
ML335	16.07 ± 0.88	13	TPenA (80 μM)	15.48 ± 0.79	14	n. s.

**Table S3: BK<sub>Ca</sub> channel competition assay statistics.**

<b>Compound</b>	<b>IC<sub>50</sub> (μM)</b>	<b>n</b>	<b>P value</b>
<b>THexA</b>	<b>0.22 ± 0.03</b>	<b>15</b>	<b>-</b>
<b>+ NS11021 (50 μM)</b>	<b>11.84 ± 1.99</b>	<b>11</b>	<b>1.28 x 10<sup>-6</sup></b>
<b>+ GoSlo-SR-5-6 (10 μM)</b>	<b>1.00 ± 0.09</b>	<b>6</b>	<b>1.84 x 10<sup>-4</sup></b>
<b>+ BL-1249 (100 μM)</b>	<b>1.56 ± 0.73</b>	<b>6</b>	<b>3.20 x 10<sup>-4</sup></b>
<b>+ DCPIB (100 μM)</b>	<b>1.50 ± 0.08</b>	<b>8</b>	<b>1.23 x 10<sup>-5</sup></b>
<b>+ ML67-33 (50 μM)</b>	<b>0.75 ± 0.18</b>	<b>7</b>	<b>5.27 x 10<sup>-4</sup></b>
<b>+ NS3623 (50 μM)</b>	<b>5.93 ± 1.52</b>	<b>7</b>	<b>3.00 x 10<sup>-5</sup></b>
<b>+ PD-118057 (10 μM)</b>	<b>0.89 ± 0.14</b>	<b>5</b>	<b>2.37 x 10<sup>-4</sup></b>
<b>+ PD-307243 (50 μM)</b>	<b>3.75 ± 0.27</b>	<b>10</b>	<b>2.56 x 10<sup>-6</sup></b>
<b>+ free Ca<sup>2+</sup> (50 μM)</b>	<b>0.26 ± 0.05</b>	<b>7</b>	<b>n. s.</b>

35. D. Simkin, E. J. Cavanaugh, D. Kim, Control of the single channel conductance of K2P10.1 (TREK-2) by the amino-terminus: role of alternative translation initiation. *J. Physiol.* **586**, 5651–63 (2008).
36. W. Kabsch, XDS. *Acta Crystallogr. D. Biol. Crystallogr.* **66**, 125–132 (2010).
37. P. Evans, Scaling and assessment of data quality. *Acta Crystallogr. D. Biol. Crystallogr.* **62**, 72–82 (2006).
38. A. J. McCoy *et al.*, Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674 (2007).
39. P. W. Bricogne G., Blanc E., Brandl M., Flensburg C., Keller P., W. T. O. Roversi P, Sharff A., Smart O.S., Vonrhein C., BUSTER version 2.10.0. (2017).
40. S. G. Brohawn, E. B. Campbell, R. MacKinnon, Domain-swapped chain connectivity and gated membrane access in a Fab-mediated crystal of the human TRAAK K<sup>+</sup> channel. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 2129–34 (2013).
41. R. K. Hite, X. Tao, R. MacKinnon, Structural basis for gating the high-conductance Ca(2<sup>+</sup>)-activated K(+) channel. *Nature.* **541**, 52–57 (2017).
42. A. Sali, T. L. Blundell, Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.* **234**, 779–815 (1993).
43. J. Chen, G. Seebohm, M. C. Sanguinetti, Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 12461–12466 (2002).
44. J. S. Mitcheson, J. Chen, M. Lin, C. Culberson, M. C. Sanguinetti, A structural basis for drug-induced long QT syndrome. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 12329–12333 (2000).
45. M. Perry *et al.*, Structural determinants of HERG channel block by clofilium and ibutilide. *Mol. Pharmacol.* **66**, 240–249 (2004).
46. Small-Molecule Drug Discovery Suite 2017, Schrödinger, New York (2017).

47. K. Lindorff-Larsen *et al.*, Improved side-chain torsion potentials for the Amber ff99SB protein force field. *Proteins*. **78**, 1950–1958 (2010).
48. P. Mark, L. Nilsson, Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K (2001), doi:10.1021/JP003020W.
49. I. S. Joung, T. E. 3rd Cheatham, Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. *J. Phys. Chem. B*. **112**, 9020–9041 (2008).
50. O. Berger, O. Edholm, F. Jähnig, Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. *Biophys. J*. **72**, 2002–2013 (1997).
51. J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, D. A. Case, Development and testing of a general amber force field. *J. Comput. Chem*. **25**, 1157–1174 (2004).
52. J. Wang, W. Wang, P. A. Kollman, D. A. Case, Automatic atom type and bond type perception in molecular mechanical calculations. *J. Mol. Graph. Model*. **25**, 247–260 (2006).
53. C. I. Bayly, P. Cieplak, W. Cornell, P. A. Kollman, A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. *J. Phys. Chem*. **97**, 10269–10280 (1993).
54. C. Ballatore, D. M. Huryn, A. B. 3rd Smith, Carboxylic acid (bio)isosteres in drug design. *ChemMedChem*. **8**, 385–395 (2013).
55. B. Hess, C. Kutzner, D. van der Spoel, E. Lindahl, GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. *J. Chem. Theory Comput*. **4**, 435–447 (2008).
56. S. Pronk *et al.*, GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. *Bioinformatics*. **29**, 845–854 (2013).
57. T. Darden, D. York, L. Pedersen, Particle mesh Ewald: An  $N \cdot \log(N)$  method for Ewald sums in large systems. *J. Chem. Phys*. **98**, 10089–10092 (1993).

58. U. Essmann *et al.*, A smooth particle mesh Ewald method. *J. Chem. Phys.* **103**, 8577–8593 (1995).
59. G. Bussi, D. Donadio, M. Parrinello, Canonical sampling through velocity rescaling. *J. Chem. Phys.* **126**, 14101 (2007).
60. M. Parrinello, A. Rahman, Polymorphic transitions in single crystals: A new molecular dynamics method. *J. Appl. Phys.* **52**, 7182–7190 (1981).
61. S. Nosé, M. L. Klein, Constant pressure molecular dynamics for molecular systems. *Mol. Phys.* **50**, 1055–1076 (1983).
62. B. Hess, H. Bekker, H. J. C. Berendsen, J. G. E. M. Fraaije, LINCS: A linear constraint solver for molecular simulations. *J. Comput. Chem.* **18**, 1463–1472 (1997).
63. C. Kutzner, H. Grubmüller, B. L. de Groot, U. Zachariae, Computational electrophysiology: the molecular dynamics of ion channel permeation and selectivity in atomistic detail. *Biophys. J.* **101**, 809–817 (2011).
64. D. P. Tieleman, H. J. C. Berendsen, Molecular dynamics simulations of a fully hydrated dipalmitoylphosphatidylcholine bilayer with different macroscopic boundary conditions and parameters. *J. Chem. Phys.* **105**, 4871 (1998).
65. D. A. Köpfer *et al.*, Ion permeation in K<sup>+</sup> channels occurs by direct Coulomb knock-on. *Science*. **346**, 352–355 (2014).
66. Schrödinger Suite Virtual Screening Workflow: Epik, Version 2.2; Glide, Version 5.7; Impact, Version 5.7; LigPrep, Version 2.5; Phase, Version 3.3; Prime, Version 2.3; SiteMap, Version 2.5; Desmond Molecular Dynamics System, Version 3.0, D. E. Shaw Research; Schrödinger, New York (2011).
67. S. Durdagi, I. Erol, R. E. Salmas, M. Patterson, S. Y. Noskov, First universal pharmacophore model for hERG1 K(+) channel activators: actHER. *J. Mol. Graph. Model.* **74**, 153–170 (2017).